TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00078988

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
Study: NCT02913742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring by depth electrode
Description: During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
Study: NCT03323996

Intervention type: OTHER
Intervention: Semi-Structured interviews
Description: individual semi-structured interviews

Intervention type: OTHER
Intervention: Semi-Structured interviews
Description: individual semi-structured interviews
Study: NCT00772694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: tablets 200mg, 400mg bid continuously in 4-week cycles
Study: NCT02611700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg,day1,weekly,until disease progression or toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg,day1,weekly,until disease progression or toxicity
Study: NCT00617656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, Docetaxel
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin
Description: Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin
Description: Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
Study: NCT03117530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
Study: NCT04180501

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SRS sequential sintilimab
Description: The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
Study: NCT03628950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSSB group
Description: At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB group
Description: The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
Study: NCT02069236

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: G6PD Test
Description: All subjects are tested by multiple G6PD tests
Study: NCT03033251

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Invasive Ventilation
Description: Patients will receive non invasive ventilation as a standard of care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Oxygen Cannula 50
Description: Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Oxygen Cannula 30
Description: Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
Study: NCT03855033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Aware Sexual Health - High School
Description: Media Aware Sexual Health is a web-based comprehensive sexual health education program for high school students that uses a media literacy approach.
Study: NCT03911778

Intervention type: OTHER
Intervention: Improvement of symptoms
Description: Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
Study: NCT01817647

Intervention type: PROCEDURE
Intervention: Colorectal surgery
Study: NCT00589147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Zimmer NexGen Legacy Knee System, modular cemented tibia
Description: modular cemented tibia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.
Description: non-modular cemented tibia.
Study: NCT01195272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 52 weeks
Study: NCT02310243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: oral, once daily (125mg, 100mg or 75mg) for 21 days
Study: NCT01411865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolkit
Description: Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
Study: NCT01826786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 (100 mg)
Description: JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
Study: NCT00777413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline 100mg Tablets
Study: NCT04636359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation
Description: The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation
Description: The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
Study: NCT03928353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 16 hour infusion
Study: NCT00281606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different formulations of once-daily lopinavir/ritonavir
Description: CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different formulations of once-daily lopinavir/ritonavir
Description: CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
Study: NCT02159781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment - scaling and root planning
Study: NCT02017860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
Study: NCT03928353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: Placebo - Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: Placebo - Sodium Chloride
Study: NCT00640679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abrupt Clopidogrel Interruption
Description: Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel Tapering
Description: Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
Study: NCT00254852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Lateral Fusion (PLF)
Description: Posterior lateral fusion (PLF) of the lumbar spine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Lateral Fusion (PLF)
Description: Posterior lateral fusion (PLF) of the lumbar spine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Lumbar Interbody Fusion (ALIF)
Description: Anterior lumbar interbody fusion (ALIF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Lumbar Interbody Fusion (ALIF)
Description: Anterior lumbar interbody fusion (ALIF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Description: Transforaminal lumbar interbody fusion (TLIF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Description: Transforaminal lumbar interbody fusion (TLIF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Description: Posterior lumbar interbody fusion (PLIF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Description: Posterior lumbar interbody fusion (PLIF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extreme lateral interbody fusion (XLIF)
Description: Extreme lateral interbody fusion (XLIF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extreme lateral interbody fusion (XLIF)
Description: Extreme lateral interbody fusion (XLIF)
Study: NCT03252418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 500 MG
Description: ascorbic acid is vitamin that can cause gingival depigmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: diode laser is soft tissue laser case photothermolysis of melanoctes
Study: NCT02944188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open right hemicolectomy plus ERAS
Description: patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
Study: NCT00589147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia
Description: non-modular uncemented tibia
Study: NCT02119026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 bid d1-14,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 7,5 mg/kg given on d1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 7,5 mg/kg given on d1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2 iv. d 1 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 200mg/m2 iv. d 1 q3w .
Study: NCT00992004

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arantal® (highly bioavailable turmeric extract)
Description: 4 capsules a day, before breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Arantal® (highly bioavailable turmeric extract)
Description: 4 capsules a day, before breakfast
Study: NCT01913860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improving GP antibiotics prescribing behaviour
Description: GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improving GP antibiotics prescribing behaviour
Description: GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
Study: NCT01712217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT13387
Description: HSP90 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT13387
Description: HSP90 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT13387
Description: HSP90 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
Study: NCT03360045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 5 cc normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Merocel
Description: Merocel packing is applied.
Study: NCT01224587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000078
Description: Oral, one single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000082
Description: Oral, one single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000083
Description: Oral, one single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000083
Description: Oral, one single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000085
Description: Oral, one single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000085
Description: Oral, one single dose
Study: NCT04929756

Intervention type: BEHAVIORAL
Intervention: Visual Feedback
Description: Gaze-contingent visual feedback

Intervention type: BEHAVIORAL
Intervention: Visual Feedback
Description: Gaze-contingent visual feedback

Intervention type: BEHAVIORAL
Intervention: Visual Feedback
Description: Gaze-contingent visual feedback

Intervention type: BEHAVIORAL
Intervention: Visual Feedback
Description: Gaze-contingent visual feedback

Intervention type: BEHAVIORAL
Intervention: Visual Feedback
Description: Gaze-contingent visual feedback
Study: NCT01383642

Intervention type: OTHER
Intervention: No intervention, observational study
Study: NCT01148316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group cognitive-behavioral therapy
Description: weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
Study: NCT03210779

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938/ATCC PTA
Description: Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
Study: NCT00794014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative strategy
Description: * Main vessel stenting was performed.~* Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow \<3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) \>75% in LM subgroup.~* Side branch stenting was performed if TIMI flow \<3 in the Side branch after ballooning in non-LM subgroup, and DS \>50% or dissection in the Side branch after ballooning in LM subgroup.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aggressive strategy
Description: * Main vessel was performed.~* Side branch ballooning and kissing ballooning were done if DS \>75% in the side branch after main vessel stenting in non-LM subgroup, and DS \>50% in LM subgroup.~* Side branch stenting was performed if DS \>50% in the side branch after ballooning in non-LM subgroup, and DS \>30% or dissection in the side branch after ballooning in LM subgroup.
Study: NCT02209649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine and Telmisartan fixed dose combination (FDC) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine and Telmisartan fixed dose combination (FDC) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacidipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan